NEUMORA THERAPEUTICS, INC. Interest Expense
NEUMORA THERAPEUTICS, INC. (NMRA) reported Interest Expense of $1.43 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2026-08-14
- NEUMORA THERAPEUTICS, INC. interest expense for the quarter ending 2026-06-30 was $1.43M, a 364.50% increase year-over-year.
- NEUMORA THERAPEUTICS, INC. interest expense for the quarter ending 2026-03-31 was $1.44M.
- NEUMORA THERAPEUTICS, INC. interest expense for the quarter ending 2025-06-30 was $307.00K.
- NEUMORA THERAPEUTICS, INC. interest expense for fiscal 2025 was $2.01M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 12 month |
|---|---|---|---|
| 2026-06-30 | $1.43M 10-Q · filed 2026-08-14 | $2.86M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $1.44M 10-Q · filed 2026-05-07 | ||
| 2025-12-31 | $2.01M 10-K · filed 2026-03-30 | ||
| 2025-06-30 | $307.00K 10-Q · filed 2026-08-14 | $307.00K 10-Q · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |